Welcome to MedArena!

Your trusted destination for CME, CPD & Medical Education across the Middle East.

Information

  • Address:MedArena Corporation
  • Call Us:1 (800) 828-2059
  • Email:support [at] medarenaevents.com
Dr. Michael J. Lenardo

Achievements

—NIH Distinguished Investigator, Former Chief of the Molecular Development of the Immune System Section, and Former Co-Director of the NIAID Clinical Genomics Program.
2019 and 2015Elected Member of the National Academy of Sciences and the National Academy of Medicine (2019), and Fellow of the American Academy of Arts and Sciences (2015).
2006Appointed Officer of the Most Excellent Order of the British Empire (O.B.E.) by Queen Elizabeth II (2006) for establishing international doctoral research partnerships.

Dr. Michael J. Lenardo

Molecular Immunologist, Geneticist, NIH Distinguished Investigator

Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health

About

Dr. Michael J. Lenardo is a world-renowned physician-scientist, molecular immunologist, and pioneer in human genetics whose career has redefined fundamental concepts of immune system regulation, programmed cell death, and targeted precision therapy for inherited immune disorders.

He completed his undergraduate studies at Johns Hopkins University, graduating with a Bachelor of Arts in Natural Sciences in 1977. He earned his Doctor of Medicine (M.D.) degree from Washington University School of Medicine in St. Louis in 1981, where he was introduced to molecular virology and molecular biology. Following clinical residency training in internal medicine and research at the University of Iowa, Dr. Lenardo conducted groundbreaking postdoctoral research at the Whitehead Institute for Biomedical Research and the Massachusetts Institute of Technology (MIT) under Nobel Laureate David Baltimore and Louis Staudt, contributing fundamental early insights into transcription factors,including the purification and regulatory characterization of NF-κκB.

In 1989, Dr. Lenardo joined the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) as an independent principal investigator. He went on to serve as Chief of the Molecular Development of the Immune System Section and Co-Director of the NIAID Clinical Genomics Program. Over more than three decades at the NIH, his laboratory integrated basic molecular biology, functional cellular assays, and clinical genomics to discover the precise molecular and genetic causes of numerous primary immunodeficiency diseases and autoimmune syndromes.

Dr. Lenardo is widely recognized for discovering activation-induced cell death (AICD) and interleukin-2 (IL-2) induced apoptosis, mechanisms critical for immune self-tolerance and preventing autoimmunity. His translational discoveries have illuminated the molecular pathobiology of several inherited human diseases, including:

  • ALPS (Autoimmune Lymphoproliferative Syndrome): Uncovering dominant Fas gene mutations driving defective lymphocyte apoptosis.
  • CHAPLE Disease (CD55 Deficiency / Veiled Intestinal Lymphangiectasia): Identifying CD55 loss leading to complement hyperactivation and demonstrating that targeted anti-C5 antibody therapy (eculizumab) can reverse life-threatening disease.
  • XMEN Disease: Discovering MAGT1 deficiency as a novel primary immunodeficiency affecting intracellular magnesium flux and immune defense against Epstein-Barr Virus (EBV).
  • PASLI Disease (PI3K-δδ Syndrome) & CHAI Disease (CTLA-4 Insufficiency): Unraveling pathway dysregulations leading to targeted biological interventions.

In addition to his laboratory breakthroughs, Dr. Lenardo's work on cellular homeostasis demonstrated how mTOR reactivation terminates autophagy and reforms functional lysosomes. He is also a passionate advocate for global scientific education, having co-founded several elite international graduate training partnerships, including the NIH Oxford-Cambridge Scholars Program, the NIH-Penn Immunology Graduate Partnership Program, and the NIH-Institut Pasteur Program.

Dr. Lenardo has received many of the highest honors awarded in biomedical science, including election to the National Academy of Sciences (2019), the National Academy of Medicine (2019), the American Academy of Arts and Sciences (2015), and appointment as an Officer of the Most Excellent Order of the British Empire (O.B.E.) by Queen Elizabeth II in 2006.

Events & Activities

Sep 25, 2026
In-Person

RAPID 2026: Recent Advances in Primary Immunodysregulation Disorders

Free

RAPID 2026: Recent Advances in Primary Immunodysregulation Disorders focuses on emerging developments in the diagnosis, evaluation, and management of primary immunodysregulation disorders. The event provides healthcare professionals with an opportunity to explore advances in immunology, genetics, targeted therapies, and multidisciplinary patient care.

Sidra Medicine

  • 3 Days
  • Sidra Medicine
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education